Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report

Cancer Chemother Pharmacol. 2009 Mar;63(4):745-8. doi: 10.1007/s00280-008-0775-x. Epub 2008 May 27.

Abstract

Background: Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses.

Case: We observed a 42-months of complete response with administration of 1-[2-tetrahydrofuryl]-5-fluorouracil mixed with uracil (UFT) in patient with platinium refractory ovarian cancer.

Conclusion: We report a complete remission of platinium refractory epithelial ovarian cancer with UFT monotherapy that was not reported previously.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Papillary / drug therapy
  • Carcinoma, Papillary / secondary
  • Carcinoma, Papillary / surgery
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / secondary
  • Cystadenocarcinoma, Serous / surgery
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery
  • Prognosis
  • Remission Induction
  • Salvage Therapy
  • Tegafur / administration & dosage
  • Treatment Outcome
  • Uracil / administration & dosage

Substances

  • Tegafur
  • Uracil